NewAmsterdam Pharma Company NAMS Change In Fair Value Of Warrants
Change In Fair Value Of Warrants at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept nams:ChangeInFairValueOfWarrants.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's change in fair value of warrants.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's change in fair value of warrants?
- NewAmsterdam Pharma Company (NAMS) reported change in fair value of warrants of -$5.94M in Q1 2026.
- How has NewAmsterdam Pharma Company's change in fair value of warrants changed year-over-year?
- NewAmsterdam Pharma Company's change in fair value of warrants increased by 56.8% year-over-year, from -$13.76M to -$5.94M.
- What is the long-term trend for NewAmsterdam Pharma Company's change in fair value of warrants?
- Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's change in fair value of warrants has grown at a 308.5% compound annual growth rate (CAGR), from $334K to $22.78M.
- What does change in fair value of warrants mean?
- This metric captures the non-cash gains or losses resulting from the revaluation of outstanding warrant liabilities at the end of each reporting period. As the fair value of these derivative instruments changes based on stock price volatility and time decay, it creates volatility in the company's reported net income. It is a critical indicator of potential dilution and financial exposure related to equity-linked financing instruments.